Please login to the form below

Not currently logged in
Email:
Password:

Severe Asthma

This page shows the latest Severe Asthma news and features for those working in and with pharma, biotech and healthcare.

AZ, Amgen file first-in-class asthma drug with the FDA

AZ, Amgen file first-in-class asthma drug with the FDA

AZ and Amgen are seeking approval for tezepelumab for the treatment of severe asthma patients, based on results from the companies’ PATHFINDER clinical programme. ... In September 2018, tezepelumab scored a breakthrough therapy designation (BTD) from

Latest news

More from news
Approximately 0 fully matching, plus 113 partially matching documents found.

Latest Intelligence

  • Exploring the potential of eosinophils Exploring the potential of eosinophils

    Working as a clinician at this time meant he was caring for patients with allergies and asthma, in particular severe asthma. ... IL5 biologic treatments would help patients with severe asthma.

  • A snapshot of… Enterprise Therapeutics A snapshot of… Enterprise Therapeutics

    In severe situations the mucus actually forms plugs which block the airways and significantly reduce lung function. ... In addition, we have the opportunity to evaluate the clinical efficacy of our drugs in other muco-obstructive lung diseases such as

  • GSK forges ahead with its dynamic COPD and asthma portfolio GSK forges ahead with its dynamic COPD and asthma portfolio

    You would imagine coronavirus would be one of those threats.”. GSK is trialling its biologic anti IL-5 drug mepolizumab, licensed for severe asthma, in eosinophilic COPD with a new phase ... Research focus. “I set up and ran a severe asthma clinic

  • The long and winding road to asthma breakthroughs The long and winding road to asthma breakthroughs

    Severe eosinophilic asthma (SEA) impacts between 5-10% of the population but they, and other severe asthma subtypes, represent 50% of the cost of asthma care expenditure. ... and adults under the age of 45 living with asthma in Europe and approximately 10

  • AstraZeneca: building a new ‘open innovation’ pharma company AstraZeneca: building a new ‘open innovation’ pharma company

    AstraZeneca launched five significant new medicines in 2017: immunotherapy Iminzi, Calquence for mantle cell lymphoma, Qtern in type 2 diabetes, Bevespi Aerosphere in COPD and Fasenra for severe asthma.

More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Article

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma. ... Head of “Living With”, Mariel Metcalfe, discusses the nature of severe asthma and severe eosinophilic asthma, and some key findings from recent studies

  • Severe Asthma Patient Story

    020 8581 2040. Address:. 1st &2nd floor,. 190 Chiswick High Road,. London. W4 1PP.

  • Research Partnership

    Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma.

More from PMHub
Approximately 2 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Personalised medicine AI
How early-stage clinical research is facilitating the new wave of personalised medicines
By Jorg Taubel...
patient diversity buckland
Patient diversity in clinical trials needs to be centre stage
By Danny Buckland...
Why empathy in digital patient recruitment is vital
This is where empathy mapping can be incredibly effective....